27 Biotechnology Stocks to Sell Now

27 Biotechnology Stocks to Sell Now

This week, 27 Biotechnology stocks are worse, according to the Portfolio Graderdatabase. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

This week, Amgen Inc.’s (AMGN) rating worsens to a D from the company’s C rating a week ago. Amgen Inc. discovers, develops, manufactures, and markets medicines for serious illnesses. For more information, get Portfolio Grader’s complete analysis of AMGN stock.

United Therapeutics Corporation (UTHR) declines this week from a C to a D. United Therapeutics Corporation is a biotechnology company that develops and commercializes therapeutic products for patients with chronic and life-threatening diseases. The company also gets F’s in earnings momentum. For more information, get Portfolio Grader’s complete analysis of UTHR stock.

Ophthotech Corp.’s (OPHT) rating weakens this week, dropping to a D versus last week’s C. The company also gets F’s in return on equity. For more information, get Portfolio Grader’s complete analysis of OPHT stock.

Acceleron Pharma Inc (XLRN) experiences a ratings drop this week, going from last week’s C to a D. The company also gets F’s in sales growth, earnings surprise, and return on equity. For more information, get Portfolio Grader’s complete analysis of XLRN stock.

Emergent BioSolutions Inc. (EBS) slips from a C to a D this week. Emergent BioSolutions Inc. develops and produces immunobiotics, pharmaceutical products that assist the body’s immune system to prevent or treat disease. The company also gets F’s in sales growth, earnings growth, earnings revisions, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of EBS stock.

Slipping from a D to a F rating, Ionis Pharmaceuticals, Inc. (IONS) takes a hit this week. The company also gets F’s in sales growth, operating margin growth, earnings growth, earnings momentum, and return on equity. For more information, get Portfolio Grader’s complete analysis of IONS stock.

Juno Therapeutics, Inc. (JUNO) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in earnings momentum and return on equity. For more information, get Portfolio Grader’s complete analysis of JUNO stock.

This is a rough week for MacroGenics, Inc. (MGNX). The company’s rating falls to D from the previous week’s C. The company also gets F’s in operating margin growth. For more information, get Portfolio Grader’s complete analysis of MGNX stock.

Cellectis SA Sponsored ADR (CLLS) earns a D this week, moving down from last week’s grade of C. For more information, get Portfolio Grader’s complete analysis of CLLS stock.

This week, Heron Therapeutics Inc (HRTX) drops from a D to a F rating. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of HRTX stock.

Pfenex, Inc. (PFNX) gets weaker ratings this week as last week’s D drops to a F. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of PFNX stock.

Cara Therapeutics Inc (CARA) experiences a ratings drop this week, going from last week’s D to a F. The company also gets F’s in sales growth, earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of CARA stock.

Slipping from a D to a F rating, Enzymotec Ltd. (ENZY) takes a hit this week. The company also gets F’s in sales growth, earnings growth, earnings surprise, and earnings momentum. For more information, get Portfolio Grader’s complete analysis of ENZY stock.

Nivalis Therapeutics, Inc. (NVLS) slips from a C to a D this week. Nivalis Therapeutics, Inc. manufactures, sells, and supports equipment used in the fabrication of chips and semiconductors. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of NVLS stock.

This is a rough week for Immune Design Corp. (IMDZ). The company’s rating falls to F from the previous week’s D. The company also gets F’s in sales growth, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMDZ stock.

vTv Therapeutics, Inc. Class A (VTVT) declines this week from a C to a D. The company also gets F’s in free cash flow. For more information, get Portfolio Grader’s complete analysis of VTVT stock.

ProQR Therapeutics N.V. (PRQR) is having a tough week. The company’s rating falls from a D to a F. The company also gets F’s in sales growth, earnings revisions, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of PRQR stock.

Aldeyra Therapeutics, Inc. (ALDX) earns a D this week, moving down from last week’s grade of C. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ALDX stock.

Progenics Pharmaceuticals, Inc. (PGNX) gets weaker ratings this week as last week’s C drops to a D. Progenics Pharmaceuticals, Inc. develops and distributes therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. The company also gets F’s in operating margin growth and return on equity. For more information, get Portfolio Grader’s complete analysis of PGNX stock.

This week, Adaptimmune Therapeutics PLC Sponsored ADR (ADAP) drops from a C to a D rating. The company also gets F’s in sales growth, earnings revisions, and return on equity. For more information, get Portfolio Grader’s complete analysis of ADAP stock.

Agenus Inc.’s (AGEN) rating weakens this week, dropping to a D versus last week’s C. Agenus Inc. is a biotechnology company that engages in developing and commercializing technologies to treat cancers and infectious diseases. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of AGEN stock.

This week, Zafgen, Inc.’s (ZFGN) rating worsens to a D from the company’s C rating a week ago. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of ZFGN stock.

This week, Vical Incorporated (VICL) drops from a D to a F rating. Vical Incorporated researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of VICL stock.

Immunomedics, Inc. (IMMU) earns a D this week, moving down from last week’s grade of C. Immunomedics, Inc. develops, manufactures, and sells diagnostic imaging and therapeutic products. The company also gets F’s in sales growth, earnings surprise, and free cash flow. For more information, get Portfolio Grader’s complete analysis of IMMU stock.

MEI Pharma, Inc. (MEIP) is having a tough week. The company’s rating falls from a C to a D. MEI Pharma, Inc. is an oncology company focused on the clinical development of novel therapeutics targeting cancer metabolism. The company also gets F’s in return on equity and free cash flow. For more information, get Portfolio Grader’s complete analysis of MEIP stock.

Aptose Biosciences Inc. (APTO) declines this week from a D to a F. The company also gets F’s in earnings surprise, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of APTO stock.

Opexa Therapeutics, Inc. (OPXA) experiences a ratings drop this week, going from last week’s C to a D. Opexa Therapeutics, Inc. develops cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, pancreatic, and cardiac conditions. The company also gets F’s in earnings revisions, earnings surprise, earnings momentum, return on equity, and free cash flow. For more information, get Portfolio Grader’s complete analysis of OPXA stock.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.


Article printed from InvestorPlace Media, https://investorplace.com/2016/11/27-biotechnology-stocks-to-sell-now-2/.

©2019 InvestorPlace Media, LLC